Responsiveness and Validation Study of MFM-20 in SMA Patients Treated With Nusinersen
study id #: NCT04644393
condition: Spinal Muscular Atrophy
status: Not yet recruiting
purpose:The Motor Function Measure (MFM), a reliable tool assessing motor function and its progression in most neuromuscular diseases, is widely used in France in many teams. It can be used regardless of the severity of the motor impairment or the ambulatory status of the patient, allowing its use throughout the whole follow-up period of the patient, even in case of the loss of walking. Two versions of the MFM exist, one composed of 32 items validated for patients from 6 years old (MFM-32) and a shorter version composed of 20 items validated for patients between 2 and 6 years old (MFM-20).
In order to show the possible use of MFM-20 as early as the age of 2 years to validly and reliably monitor the evolution of the motor function of children treated with Nusinersen, we propose in this project to study the sensitivity to treatment-induced change of MFM-20 and the validity of the scale in this population.
results: https://clinicaltrials.gov/ct2/show/results/NCT04644393
last updated: February 04, 2022
-
Spinal Muscular Atrophy and TypesWhat is Spinal Muscular Atrophy?Spinal m...
-
Targeted NGS Seen as Best When Screening for SMA and Its CarriersTargeted next generation sequencing (NGS...
-
Springfield Second-Grader Attends Class From Home Through Double RoboticsElliette “Ellie” Miller, 8, was diag...
-
Sofia’s Story – Johns Hopkin’sOn the morning of Friday, Aug. 23, 2019,...
-
New Gene Therapy Transforms SMA (Spinal Muscular Atrophy)https://www.youtube.com/watch?v=C5Dl3iMv...
-
Neurogenic Arthrogryposis and the Power of PhenotypingIn this article we review the commonest ...
-
Biogen Exercises Option With Ionis to Develop and Commercialize Investigational ASO for SMABiogen, Inc. and Ionis Pharmaceuticals, ...